AbCellera Biologics Inc.

ABCL

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors Driehaus Capital

AI Signal

**Signal Note: Baker Bros.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ABaker Bros. Advisors9.3%Nov 14, 2024

SC 13GBaker Bros. Advisors7.9%Feb 14, 2024

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 27,525,640Value: $94.1M

**Signal Note: Baker Bros. Initiates Major Position in AbCellera Biologics (ABCL)** Baker Bros.' new ~27.5M share position in ABCL is notable given their track record of concentrated, conviction-driven bets in biotech, though the reported dollar value (~$94B) appears to be a data error — at recent prices (~$3-4/share), this stake is likely worth ~$80-110M, representing a meaningful but more realistic allocation. AbCellera is a drug discovery platform company (not a single-asset story), partnering with pharma to generate antibody therapeutics across multiple indications; the key value driver is its expanding royalty/milestone stream from partnered programs, including candidates in oncology and immunology moving through mid-stage development. Baker Bros. may be positioning ahead of anticipated partner pipeline readouts and potential validation of ABCL's platform economics as

Driehaus CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS2 funds ARGX2 funds ARWR2 funds BEIGF2 funds NUVL2 funds DSGN2 funds CELC2 funds EWTX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Driehaus Capital Initiates ABCL Position** Driehaus' $12.9M entry into AbCellera suggests conviction in the company's antibody discovery platform and near-term clinical readouts, likely driven by upcoming data in their lead programs (OKT019 for lupus nephritis expected 2024-2025, and partnered assets with Eli Lilly). The position size and growth-focused investor profile indicate belief in either near-term clinical validation or platform monetization via partnerships, though ABCL's platform-dependent valuation carries execution risk on discovery success rates.